Team:Yale/Project
ampersand: an Anti-Microbial Peptide Coating |
|||||||||||
The ProblemThe Problem: | |||||||||||
Our SolutionThe Solution: To address this issue, we aimed to develop an anti-microbial peptide composed of two components, which we envision can be modulated to suit a variety of functional adhesive applications. The ideal anti-microbial peptide coating would exhibit both biofilm-inhibitory activity as well as strong adhesion to a variety of substrates. In addition, we sought to identify a biomimetic adhesive domain so as to enhance the environmental friendliness of our peptide. Mussel adhesive proteins (MAPs), which are secreted by the mussel to help it anchor and survive in the harsh conditions of the intertidal zone, are an effective and environmentally sound adhesive domain. As our anti-microbial domain, we selected LL-37, a member of the cathelicidin family of peptides, due to the potency of its toroidal pore mechanism of lipid bilayer disruption. MAPs selectively attach to inorganic and organic surfaces via L-dopamine (L-DOPA), which is generated by post-translational modification of tyrosine with tyrosinase (often secreted along with the MAPs by the mussels in an enzyme cocktail that assists with the crosslinking of MAPs). Our study sought to be the first to synthesize an entire recombinant anti-microbial adhesive peptide without the need for post-translational modifications. We incorporated L-DOPA, a nonstandard amino acid, into our construct using a genetically recoded organism (GRO). Because this peptide is toxic to the GRO in which it is produced, we designed a better controlled inducible system that limits basal expression. This was achieved through a novel T7 riboregulation system that controls expression at both the transcriptional and translational levels. This improved system is a precise synthetic switch for the expression of cytotoxic substances in the already robust T7 system. Lastly, a variety of tests were carried out to characterize our recombinant protein in comparison to the commercially available MAP-based adhesive, Cell-TakTM. |
|||||||||||
Project Goals
1. Create a T7 Riboregulation System to control the expression of our proteins:
2. Design the anti-biofouling peptide using both a modular approach:
3. Develop an erosion rig to assess the strength of the adhesive peptide:
|
|||||||||||
Introduction
Biofilm formation: A problem in clinics and cargo ships
An improved T7 Riboregulation System
A DOPA-containing peptide derived from mussel foot protein
Anti-biofouling Peptide: LL-37 |
|||||||||||
T7 Riboregulation System: Experimental Design
Strains, Plasmids, and Reagents
Two Levels of Regulation for T7 Polymerase Expression |
|||||||||||
Anti-Fouling Peptide Construct: Experimental DesignWe hypothesize that we can develop an improved version of the current adhesives by developing a fusion protein of Mgfp-5 with Mefp-1 as the anchoring region for the anti-biofouling peptide. An integral part of developing this peptide is to co-translationally insert L-DOPA into our peptide, which has never been done before with mussel foot proteins (Figure 5). In this process of orthogonal translation, we first will get rid of the UAG stop codon and then transform the strain to synthesize tRNA and tRNA transferase that corresponds to the UAG codon and the L-DOPA non-standard amino acid to develop the GRO. The advantage of this procedure is that we have the ability to skip the time-consuming and inefficient tyrosinase enzyme treatment step.
Protein Purification
We plan to purify the protein by using the Twin Strep Tag in tandem with the Flag tag, which was included in out master construct of the anti-biofouling peptide (Figure 6). The Flag tag is perfectly cleavable by the enzyme enterokinase. The FLAG tag is made up of 8 amino acids and works well for low-abundance proteins. It is hydrophilic, so it will most likely not interfere with protein folding and function of the target protein. The Strep tag is also made up of 8 amino acids that will not disturb the protein’s functions. We chose the FLAG tag because it is perfectly cleavable. Info on LL-37 and N-terminus? The protein will be purified in a Strep-Tactin® Sepharose® column. In order to address the L-DOPA adhesive L-DOPA component, our final step is to elute with a base to reduce the amount of the anti-biofouling peptide that sticks to the column due to L-DOPA adhesion (Figure 7).
|
|||||||||||
Characterization of Coating Adhesion PropertiesWe hypothesize that we can develop an improved version of the current adhesives by developing a fusion protein of Mgfp-5 with Mefp-1 as the anchoring region for the anti-biofouling peptide. An integral part of developing this peptide is to co-translationally insert L-DOPA into our peptide, which has never been done before with mussel foot proteins (Figure 5). In this process of orthogonal translation, we first will get rid of the UAG stop codon and then transform the strain to synthesize tRNA and tRNA transferase that corresponds to the UAG codon and the L-DOPA non-standard amino acid to develop the GRO. The advantage of this procedure is that we have the ability to skip the time-consuming and inefficient tyrosinase enzyme treatment step.
Protein Purification
We plan to purify the protein by using the Twin Strep Tag in tandem with the Flag tag, which was included in out master construct of the anti-biofouling peptide (Figure 6). The Flag tag is perfectly cleavable by the enzyme enterokinase. The FLAG tag is made up of 8 amino acids and works well for low-abundance proteins. It is hydrophilic, so it will most likely not interfere with protein folding and function of the target protein. The Strep tag is also made up of 8 amino acids that will not disturb the protein’s functions. We chose the FLAG tag because it is perfectly cleavable. Info on LL-37 and N-terminus? The protein will be purified in a Strep-Tactin® Sepharose® column. In order to address the L-DOPA adhesive L-DOPA component, our final step is to elute with a base to reduce the amount of the anti-biofouling peptide that sticks to the column due to L-DOPA adhesion (Figure 7).
|